Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis

ISSN： 0937-941X

Source： Osteoporosis International, Vol.19, Iss.8, 2008-08, pp. : 1125-1138

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The development of parathyroid hormone as anabolic therapy for osteoporosis: A timeline

By Dempster David Reeve Jonathan

Clinical Review in Bone and Mineral Metabolism, Vol. 4, Iss. 4, 2006-12 ,pp. : 227-231

Humana Press, Inc

Access to resources Recommend Favorite

2MD, a new anabolic agent for osteoporosis treatment

By Plum Lori Fitzpatrick Lorraine Ma Xiaohong Binkley Neil Zella Julia Clagett-Dame Margaret DeLuca Hector

Osteoporosis International, Vol. 17, Iss. 5, 2006-05 ,pp. : 704-715

Springer Publishing Company

Access to resources Recommend Favorite

Anabolic therapy for osteoporosis

By Bilezikian John P

Women's Health, Vol. 3, Iss. 2, 2007-03 ,pp. : 243-253

Future Medicine

Access to resources Recommend Favorite

Emerging Anabolic Treatments in Osteoporosis

Current Drug Safety, Vol. 6, Iss. 2, 2011-04 ,pp. : 62-74

Bentham Science Publishers

Access to resources Recommend Favorite

Osteoporosis: Pathophysiology and new drug development

By Vondracek Sheryl Chen Judy Csako Gyorgy

Clinical Review in Bone and Mineral Metabolism, Vol. 2, Iss. 4, 2004-12 ,pp. : 293-313

Humana Press, Inc

Access to resources Recommend Favorite